Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Treasury Shares: 2023-2024

Historic Treasury Shares for 4D Molecular Therapeutics (FDMT) over the last 2 years, with Dec 2024 value amounting to $361,997.

  • 4D Molecular Therapeutics' Treasury Shares rose 112.38% to $698,019 in Q3 2025 from the same period last year, while for Sep 2025 it was $698,019, marking a year-over-year increase of 112.38%. This contributed to the annual value of $361,997 for FY2024, which is 99.80% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Treasury Shares is $361,997, which was up 99.80% from $181,181 recorded in FY2023.
  • 4D Molecular Therapeutics' 5-year Treasury Shares high stood at $361,997 for FY2024, and its period low was $181,181 during FY2023.
  • Over the past 2 years, 4D Molecular Therapeutics' median Treasury Shares value was $271,589 (recorded in 2023), while the average stood at $271,589.
  • Data for 4D Molecular Therapeutics' Treasury Shares shows a peak YoY surged of 99.80% (in 2024) over the last 5 years.
  • 4D Molecular Therapeutics' Treasury Shares (Yearly) stood at $181,181 in 2023, then skyrocketed by 99.80% to $361,997 in 2024.